Login to Your Account


Cempra Inc. shares rose 28.6 percent on Friday as the company reported that early clinical responses to its oral antibiotic, Taksta, proved noninferior to those for Pfizer Inc.’s oral Zyvox during a phase III trial.

more »


Myovant Sciences Inc.'s kickoff to 2017 with a phase III trial testing its oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix in uterine fibroids (UFs) signaled a year of tighter focus on the condition, with a group of heavyweight drug developers involved in that indication as well as endometriosis.

read more »


Partners in Focus